2nd April 2008 - AGI Therapeutics plc ("AGI" or the "Company") (AIM, IEX: AGI), a speciality pharmaceutical company focused on gastrointestinal drug products, announces the key findings of a clinical study to assess the pharmacokinetic profile of arbaclofen (AGI-006), which is being developed for the treatment of gastroparesis, a significant gastric condition amongst diabetics. The pharmacokinetic study was conducted in healthy human volunteers and compared the drug exposure profile of arbaclofen, under both fasted and fed conditions, following a single oral administration of a 5mg dose. Arbaclofen contains the purified R-isomer form of the previously approved drug baclofen (which is an equal mixture of the S- and R-isomers). In addition, this study compared the drug exposure of arbaclofen (5mg), in terms of both the S- and R-isomer forms of baclofen, with a single 10mg oral dose of Lioresal® (a marketed form of racemic baclofen)... AGI Therapeutics' Press Release -
